Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways
Pharmacology Research & Perspectives · 2026-04 · 14 (2)
DOI: 10.1002/prp2.70219 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 26.03.2026. Verfasst von Andrej Belančić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Interleukin-6 Inhibitors, Pain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is an autoimmune systemic disease in which pain remains a major and often refractory symptom even after clinical remission of the disease. Although historically attributed to joint inflammation, recent evidence reveals a multifactorial pathogenesis of RA pain, involving peripheral sensitization, central sensitization, and neuroimmune crosstalk. In these mechanisms, interleukin‐6 (IL‐6) plays a central role not only as one of the inflammatory mediators but also as a classic and trans‐signaling modulator for pain. This review synthesizes current mechanistic and clinical evidence on IL‐6 inhibitors, particularly sarilumab and tocilizumab, concerning their effect on pain in RA. Preclinical studies have already demonstrated that IL‐6 enhances the excitability of nociceptors through the upregulation of ion channels in dorsal root ganglia; it also promotes glial activation within the spinal cord; however, chronic pain sustains these processes. Blockade of IL‐6 receptor reverses these changes and alleviates mechanical hyperalgesia as well as allodynia in different models of diseases. Clinical trials of IL‐6 inhibitors have shown that these compounds provide major pain relief, sometimes better than tumor necrosis factor (TNF) inhibitors, most explicitly for patients with elevated baseline C‐reactive protein (CRP) or who do not respond to TNF inhibitors. Differences in their pharmacokinetics, receptor binding, and suppression of CRP may translate into differences in their analgesic profiles. However, it is analyzed that a subset of patients with persistently painful rheumatoid arthritis despite IL‐6 inhibition demonstrates the existence of non‐inflammatory drivers like nociplastic pain and the inadequacy of conventional indices of disease activity to capture the burden of pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
- Department of Pediatrics, Division of Pediatric Rheumatology, Adana City Training and Research Hospital, Adana, Turkiye.
- Department of Pathophysiology, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
- Sestre Milosrdnice University Hospital Center, School of Medicine, Catholic University of Croatia, Zagreb, Croatia.
- Department of Internal Medicine, General Hospital "Dr. Josip Benčević", Slavonski Brod, Croatia.
- Department of Internal Medicine, Division of Nephrology and Dialysis, University Hospital of Split, Split, Croatia.
ORCID-Profile: Andrej Belančić, Almir Fajkić, Mirjana Stanić Benić
Zitieren
APA
Belančić, A., Sener, S., Fajkić, A., Potočnjak, I., Benić, M. S., Vučković, M., Sener, Y. Z., Pavlović, M. R., Markotić, A., Radić, J., & Radić, M. (2026). Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways. Pharmacology Research & Perspectives, 14(2). https://doi.org/10.1002/prp2.70219
Vancouver
Belančić A, Sener S, Fajkić A, Potočnjak I, Benić MS, Vučković M, et al. Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways. Pharmacology Research & Perspectives. 2026;14(2). doi:10.1002/prp2.70219
BibTeX
@article{Belani2026,
author = {Belančić, Andrej and Sener, Seher and Fajkić, Almir and Potočnjak, Ines and Benić, Mirjana Stanić and Vučković, Marijana and Sener, Yusuf Ziya and Pavlović, Marija Rogoznica and Markotić, Antonio and Radić, Josipa and Radić, Mislav},
title = {Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/prp2.70219}
}
EUVIMED